Navigation Links
Accera, Inc. Completes $35 Million Series C Financing
Date:11/11/2008

BROOMFIELD, Colo., Nov. 11 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced it has recently closed a Series C financing round of $35 million (euro 27 million), led by Inventages Venture Capital SA. Proceeds of this financing will be used to begin sales and marketing of the company's lead product, Axona(TM) (previously known as Ketasyn), which is scheduled to launch in the United States in the first quarter of 2009.

Inventages was joined in this round by San Diego-based POSCO BioVentures and other previous private investors. Inventages and POSCO participated in the Company's Series A and B rounds.

Steve Orndorff, Ph.D., Accera's founder and CEO, said, "Closing this transaction in the current difficult financial environment is a testament to the confidence of our investors in the Accera organization and the potential of Axona".

Wolfgang Reichenberger, Ph.D., general partner, Inventages WHealth Management Inc. and IVC Americas SA and a member of Accera's Board of Directors, expressed enthusiasm about the commercial direction of the company and the upcoming launch of Axona. "Metabolic intervention is a new approach to neurodegenerative diseases, and Accera is a clear leader. We are pleased to support the commercialization of Axona as the lead product from this novel technology platform," Reichenberger said.

About Accera, Inc.

Accera, Inc., a privately held biotechnology company, discovers and develops breakthroughs in central nervous systems disorders. Accera's novel approaches positively impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, Accera is developing products that address metabolic deficiencies by providing an alternative energy source for the brain. For more information, visit http://www.accerapharma.com.

Contacts

Media: Investors:

Kelly McKenna Greg Kading

MS&L Worldwide Vice President, Finance

(415) 293-2808 Accera, Inc.

Kelly.mckenna@mslworldwide.com (303) 999-3704

gkading@accerapharma.com


'/>"/>
SOURCE Accera, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
2. Accera, Inc. to Present at the 4th Annual BIO Investor Forum
3. OncoMed Pharmaceuticals Completes Series B Financing
4. Avantium Completes EUR 18 Million Financing Round
5. Advanced Life Sciences Completes Debt Transaction
6. American Oriental Bioengineering Completes Two Acquisitions
7. Acasti Pharma completes offer to exchange outstanding Neptune Technologies dividend notes
8. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
9. S*BIO Completes US$26 Million Equity Financing
10. Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
11. CeNeRx BioPharma Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... (PRWEB) , ... January 24, ... ... commercial provider of distributed wastewater treatment and resource recovery solutions, announced that ... award-winning EcoVolt® solution. The solution will provide Rombauer with the ability to ...
(Date:1/24/2017)... 2017  Neogen Corporation (NASDAQ: NEOG ) ... SenesTech Incorporated (NASDAQ: SNES ) related to ... by SenesTech. The two firms had worked together since ... product was approved by the U.S. Environmental Protection Agency. ... product could only be used by a Licensed Pesticide ...
(Date:1/24/2017)... DURHAM, N.C. , Jan. 24, 2017 /PRNewswire/ ... and technology, announces that Daniel Eisenman , Ph.D., ... Officer. In his new role, Dr. ... manage a forthcoming institutional biosafety committee (IBC) service. He ... the IBC landscape. The new IBC service represents Schulman,s ...
(Date:1/24/2017)... Jan. 24, 2017  Asterias Biotherapeutics, Inc. (NYSE ... of regenerative medicine, today announced positive efficacy results ... trial that showed additional motor function improvement at ... AST-OPC1 cells in AIS-A patients with complete cervical ... upper extremity motor function is critically important to ...
Breaking Biology Technology:
(Date:12/16/2016)... The global wearable medical device market, in terms of ... USD 5.31 billion in 2016, at a CAGR of 18.0% during ... ... in medical devices, launch of a growing number of smartphone-based healthcare ... healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... -- ... Research and Markets has announced the addition of the "Global Military ... report forecasts the global military biometrics market to grow at a CAGR ... been prepared based on an in-depth market analysis with inputs from industry ... the coming years. The report also includes a discussion of the key ...
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
Breaking Biology News(10 mins):